As African countries continue to experience increasing coronavirus infections, with the overall number of cases exceeding 3.79 million mid-February, Russia is stepping in to supply 300 million doses of Sputnik V vaccine through the African Union (AU). It an effort to assist to stop further spread of the pandemic on the continent.
An official release said that the Africa Vaccine Acquisition Task Team, set up by the African Union to acquire additional vaccine doses so that Africa can attain a target immunization of 60%, has received an offer of 300 million Sputnik V vaccines from the Russian Federation. This includes a financing package for any member states wishing to secure this vaccine.
Meanwhile, the Task Team advises that the 270 million doses previously secured from AstraZeneca, Pfizer and Johnson & Johnsons were all taken up by the first allocation phase deadline through the African Medical Supplies Platform (AMSP). With these additional 300 million Sputnik V vaccines, AMSP accelerates online COVID-19 vaccines pre-orders for the 55 African Union member states.
“The Sputnik V vaccine from the Russian Federation is now available on the AMSP for the consideration of our AU Member States,“ says Dr John Nkengasong, Director of the Africa Centers for Disease Control and Prevention (Africa CDC). “Bilateral and private sector partnerships such as these aid our efforts to bringing the COVID-19 pandemic to an end.“
Nkengasong is worried that vaccine apartheid will have dire consequences for Africans in the near future. According to him, the continent needed to be taken along by the developed world as they vigorously roll out inoculation efforts. Africa’s rollout has been relatively slower with over a third of African countries yet to receive doses.
About Africa’s lack of vaccines, he said: “That is absolutely one of our greatest concerns, that the vaccine situation will continue to exacerbate the inequality gap that exists in the world especially the north – south divide. My greatest fear is that once the United States and Europe get the vaccine, they begin to impose the need to have vaccine certificate to travel and that is extremely complicated for Africans to travel across the world.”
Nkengasong added: “Africa has to team up with development partners to achieve its 60% continent-wide vaccination in the next two years. I think that is why we should as a collective of the continent, and of course, in partnership with the developed world make sure that Africa has a timely access to vaccines to meet our vaccination targets.”
While details, including clinical and technical information, are now accessible on the Africa Medical Supplies Platform (AMSP), Sputnik V vaccines will be available for a period of 12 months commencing by May 2021.
The African Union member states that wish to secure funding should approach the African Export-Import Bank through their Central Banks, as has been the case with the other vaccines that have been on offer. The lender approved US$2 billion for participating suppliers, allowing the finalization of supply contracts.
According to the Russian Direct Investment Fund (RDIF), Sputnik V is one of the world’s top three coronavirus vaccines in terms of the number of approvals issued by government regulators.
Sputnik V had been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon and San Marino.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, has said that Sputnik V has a number of key advantages:
• Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world’s oldest and most respected medical journals; It is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.
• The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
• Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
• The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
• The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
• There are no strong allergies caused by Sputnik V.
• The price of Sputnik V is less than $10 per shot, making it affordable around the world.
Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow.
About the Afreximbank: The African Export-Import Bank (Afreximbank) is a Pan-African multilateral financial institution with the mandate of financing and promoting intra-and extra-African trade. Afreximbank was established in October 1993 and owned by African governments, the African Development Bank and other African multilateral financial institutions as well as African and non-African public and private investors. The Bank was established under two constitutive documents, an Agreement signed by member states, which confers on the Bank the status of an international organization, and a Charter signed by all Shareholders, which governs its corporate structure and operations.
About the Africa CDC: Africa Centres for Disease Control and Prevention (Africa CDC), is a specialized technical institution of the African Union that strengthens the capacity and capability of Africa’s public health institutions as well as partnerships to detect and respond quickly and effectively to disease threats and outbreaks, based on data-driven interventions and programmes.
About the AVATT: The African Vaccine Acquisition Task Team (AVATT), was established by African Union Chair, President Cyril Ramaphosa, as a component in support of the Africa Vaccine Strategy that was endorsed by the AU Bureau of Heads of State and Government on 20th of August 2020. The AVATT is chaired by President Ramaphosa and includes African Union Commission Chairperson Moussa Faki Mahamat, Dr. Zweli Lawrence Mkhize, Mr. Strive Masiyiwa, Dr. Donald Kaberuka, Professor Benedict Oramah, H.E. Amira Elfadil, Dr. John Nkengasong and others, as to be nominated by the Chair of the African Union and the Chairperson of the Commission.
About the AMSP: The Africa Medical Supplies Platform (AMSP) is a non-profit initiative launched by the African Union as an immediate, integrated and practical response to the Covid-19 pandemic. The online platform was developed under the leadership of the African Union Special Envoy, Strive Masiyiwa and powered by Janngo on behalf of the African Union’s Africa Centers for Disease Control and Prevention (Africa CDC) and in partnership with African Export-Import Bank (Afreximbank) and United Nations Economic Commission for Africa (ECA) with the support of leading African and international Institutions, Foundations and Corporations as well as Governments of China, Canada and France.